# Shenzhen Xbiome Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-xbiome-biotech-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.xbiome.cn
- Total disclosed funding: $100M
- Latest round: Series B (Dec 22, 2021)
- Investors on record: 12

## About

Established in 2017 and based in Shenzhen, China, Shenzhen Xbiome Biotech Co., Ltd. operates as an artificial intelligence pharmaceutical company focuses on intestinal drug development. The core team is from Harvard University, Massachusetts Institute of Technology, Stanford University, Johns Hopkins University. The company has completed 5 rounds of funding as of 2021.

The company is mainly engaged in the mitigation or treatment of intestinal and other systemic diseases through fecal bacteria transplantation, formula bacteria and other microbial treatment methods.

The company plan to use the series B funding for the development of drug clinical trials, IND application projects in the United States and China, research and development of candidate drug pipelines.

## Funding rounds

- Series B, Dec 22, 2021, $100M — Legend Capital, 5Y Capital, Tiantu Capital, Primavera Capital Group, Gaorong Ventures, Sky 9 Capital, Hike Capital
- Series B, Nov 27, 2020 — Legend Capital, 5Y Capital, Yayi International, Primavera Capital Group, YiMei Capital, Gaorong Ventures, Alwin Capital
- Series B, Nov 2, 2019 — Legend Capital, 5Y Capital, Gaorong Ventures, Alwin Capital
- Series A, Jan 3, 2019 — Alwin Capital, Zhuhai Zijing Hongxin Investment Management
- Series A, Aug 3, 2018 — 5Y Capital, ZhenFund, Gaorong Ventures

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A, Series B
- Alwin Capital — Series A, Series B
- Zhuhai Zijing Hongxin Investment Management — Series A
- Legend Capital — Series B
- Yayi International — Series B
- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series B
- YiMei Capital (https://capitalatlas.ai/funds/yimei-capital) — Series B
- Tiantu Capital (https://capitalatlas.ai/funds/tiantu-capital) — Series B
- Sky 9 Capital (https://capitalatlas.ai/funds/sky-9-capital) — Series B
- Hike Capital (https://capitalatlas.ai/funds/hike-capital) — Series B